Latest News
-
Researchers Test Stem Cell–Based Retinal Implant for Dry AMD With Encouraging Results
Physicians and researchers at the USC Roski Eye Institute have collaborated with other California institutions to show that a firs…
from EyewireToday.com
-
GenSight Biologics Announces Topline Results from Phase 3 Clinical Trial of GS010 in Patie…
GenSight Biologics announced that a phase 3 study of GS010 (rAAV2/2-ND4) in patients with Leber hereditary optic neuropathy (LHON) failed to…
from EyewireToday.com
-
Treat-Extend-Stop Protocol for Wet AMD: Long-term Outcomes
A retrospective chart review was performed for 71 eyes of 67 patients with neovascular age-related macular degeneration (AMD) treated with i…
from EyewireToday.com
-
Patients Regain Sight After Being First to Get Retinal Tissue Engineered From Stem Cells
The first patients to receive a new treatment derived from stem cells for people with wet age-related macular degeneration (AMD) have regain…
from EyewireToday.com
-
Children’s Hospital Los Angeles Treats First Patient on the West Coast Using Gene Therap…
Surgeons of The Vision Center at Children's Hospital Los Angeles completed a revolutionary gene replacement procedure on Tuesday, March …
from EyewireToday.com
-
Research Shows Sustained Vision Improvement Among People With Most Common Cause of Blindne…
A major, 2-year European Research Council-funded program involving over 100 people diagnosed with early stages of age-related macular …
from EyewireToday.com
-
Google's AI Program: Building Better Algorithms for Detecting Eye Disease
The ability of artificial intelligence (AI) to help screen patients for a common diabetic eye disease gains momentum with a new study publis…
from EyewireToday.com
-
Market Scope: Surgery Growth Will Drive Retinal Device Market to $2.5 Billion by 2023
Surgeons use more specialized products in retinal surgery than any other ophthalmic surgical subspecialty, and these devices will account fo…
from EyewireToday.com
-
Aerpio Pharmaceuticals Presents Analysis from TIME-2 Study Regarding Effects of AKB-9778 o…
Aerpio Pharmaceuticals announced that renal function data from the TIME-2 phase 2a study of AKB-9778 in the treatment of patients with diabe…
from EyewireToday.com
-
Apellis Pharmaceuticals Announces 18-Month Results of Phase 2 Study (FILLY) of APL-2 in Ge…
Apellis Pharmaceuticals will provide an update with 18-month data on its phase 2 trial (FILLY) of its complement C3 inhibitor, APL-2, in pat…
from EyewireToday.com
-
Second Sight Announces Market Entry into Singapore with First Implant of Argus II Retinal …
Second Sight Medical Products announced market entry into Singapore, with the first patient implanted with the Company’s Argus II Reti…
from EyewireToday.com
-
Anti-VEGF Agents Improve Vision Despite Ongoing Diabetic Macular Edema
In patients with diabetic macular edema (DME), aflibercept and ranibizumab are more effective than bevacizumab in preventing disease persist…
from EyewireToday.com
-
Award Winning Algorithm Could Improve Accuracy and Speed of Diagnosis of Retinal Disease …
A new technique for identifying and diagnosing damage to the human retina has been awarded ‘Best Student Paper’ at the industry-…
from EyewireToday.com
-
Phase 2 Data Support Potential for Novel Anti-VEGF/Anti-Angiopoietin-2 Bispecific Antibody…
Genentech announced encouraging results from the phase 2 BOULEVARD study. In people with vision loss from diabetic macular edema (DME), trea…
from EyewireToday.com
